UPCOMING SESSIONS in ET
Fri, Jun 26, 2026
5:00 – 6:00 AM Bangkok
Courageous Optimism in Practice: Tools for Navigating Illness & Uncertainty David Berez Click to Register
UPCOMING SESSIONS in ET
Fri, Jun 26, 2026 · 5:00 – 6:00 AM Bangkok
Courageous Optimism in Practice: Tools for Navigating Illness & Uncertainty
David Berez
Click to Register
View all sessions

Hereditary Transthyretin Amyloidosis (hATTR) Market Trends, Innovation, and Future Growth Outlook to 2036 - DelveInsight |Alnylam Pharma, Ionis Pharma, Novo Nordisk, AstraZeneca, Pfizer, Intellia

Source
openPR

The Key Hereditary Transthyretin Amyloidosis Companies in the market include - Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia Therapeutics, Regeneron, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others.

DelveInsight's "Hereditary Transthyretin Amyloidosis Market Insights, Epidemiology, and Market Forecast-2036 report offers an in-depth understanding of the Hereditary Transthyretin Amyloidosis, historical and forecasted epidemiology as well as the Hereditary Transthyretin Amyloidosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.